» Articles » PMID: 10087226

Characterization of a Neutralization-escape Variant of SHIVKU-1, a Virus That Causes Acquired Immune Deficiency Syndrome in Pig-tailed Macaques

Overview
Journal Virology
Specialty Microbiology
Date 1999 Mar 24
PMID 10087226
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

A chimeric simian-human immunodeficiency virus (SHIV-4) containing the tat, rev, vpu, and env genes of HIV type 1 (HIV-1) in a genetic background of SIVmac239 was used to develop an animal model in which a primate lentivirus expressing the HIV-1 envelope glycoprotein caused acquired immune deficiency syndrome (AIDS) in macaques. An SHIV-infected pig-tailed macaque that died from AIDS at 24 weeks postinoculation experienced two waves of viremia: one extending from weeks 2-8 and the second extending from week 18 until death. Virus (SHIVKU-1) isolated during the first wave was neutralized by antibodies appearing at the end of the first viremic phase, but the virus (SHIVKU-1b) isolated during the second viremic phase was not neutralized by these antibodies. Inoculation of SHIVKU-1b into 4 pig-tailed macaques resulted in severe CD4(+) T cell loss by 2 weeks postinoculation, and all 4 macaques died from AIDS at 23-34 weeks postinoculation. Because this virus had a neutralization-resistant phenotype, we sequenced the env gene and compared these sequences with those of the env gene of SHIVKU-1 and parental SHIV-4. With reference to SHIV-4, SHIVKU-1b had 18 and 6 consensus amino acid substitutions in the gp120 and gp41 regions of Env, respectively. These compared with 10 and 3 amino acid substitutions in the gp120 and gp41 regions of SHIVKU-1. Our data suggested that SHIVKU-1 and SHIVKU-1b probably evolved from a common ancestor but that SHIVKU-1b did not evolve from SHIVKU-1. A chimeric virus, SHIVKU-1bMC17, constructed with the consensus env from the SHIVKU-1b on a background of SHIV-4, confirmed that amino acid substitutions in Env were responsible for the neutralization-resistant phenotype. These results are consistent with the hypothesis that neutralizing antibodies induced by SHIVKU-1 in pig-tailed macaque resulted in the selection of a neutralization-resistant virus that was responsible for the second wave of viremia.

Citing Articles

Novel Compound Inhibitors of HIV-1 Vpu.

Robinson C, Lyddon T, Gil H, Evans D, Kuzmichev Y, Richard J Viruses. 2022; 14(4).

PMID: 35458546 PMC: 9024541. DOI: 10.3390/v14040817.


Protection against SHIV-KB9 infection by combining rDNA and rFPV vaccines based on HIV multiepitope and p24 protein in Chinese rhesus macaques.

Li C, Shen Z, Li X, Bai J, Zeng L, Tian M Clin Dev Immunol. 2012; 2012:958404.

PMID: 22474488 PMC: 3299295. DOI: 10.1155/2012/958404.


Heavily glycosylated, highly fit SIVMne variants continue to diversify and undergo selection after transmission to a new host and they elicit early antibody dependent cellular responses but delayed neutralizing antibody responses.

Eastman D, Piantadosi A, Wu X, Forthal D, Landucci G, Kimata J Virol J. 2008; 5:90.

PMID: 18680596 PMC: 2518139. DOI: 10.1186/1743-422X-5-90.


Human immunodeficiency virus type 1 Vpu protein interacts with CD74 and modulates major histocompatibility complex class II presentation.

Hussain A, Wesley C, Khalid M, Chaudhry A, Jameel S J Virol. 2007; 82(2):893-902.

PMID: 17959659 PMC: 2224584. DOI: 10.1128/JVI.01373-07.


Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection.

Eda Y, Murakami T, Ami Y, Nakasone T, Takizawa M, Someya K J Virol. 2006; 80(11):5563-70.

PMID: 16699037 PMC: 1472178. DOI: 10.1128/JVI.02095-05.